Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Geratherm Medical AG's EV-to-EBIT or its related term are showing as below:
XTER:GME'
s EV-to-EBIT Range Over the Past 10 Years
Min: -10.9 Med: 16.37 Max: 97.88
Current: -8.31
During the past 13 years, the highest EV-to-EBIT of Geratherm Medical AG was 97.88. The lowest was -10.90. And the median was 16.37.
XTER:GME's EV-to-EBIT is ranked worse than 100% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.665
vs XTER:GME: -8.31
Geratherm Medical AG (XTER:GME) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Geratherm Medical AG's Enterprise Value for the quarter that ended in Dec. 2025 was €8.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geratherm Medical AG EV-to-EBIT Related Terms
Geratherm Medical AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Geratherm Medical AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Geratherm Medical AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geratherm Medical AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Geratherm Medical AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Geratherm Medical AG's EV-to-EBIT falls into.
Geratherm Medical AG's current Enterprise Value is €6.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Geratherm Medical AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geratherm Medical AG (XTER:GME) has a EV-to-EBIT of -8.19 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Geratherm Medical AG and its competitors. According to the industry distribution chart, Geratherm Medical AG ranks #999999 out of 472 companies in the Medical Devices & Instruments industry.
Is Geratherm Medical AG's EV-to-EBIT too high?
Geratherm Medical AG's current EV-to-EBIT is -8.19. Based on the distribution chart, Geratherm Medical AG ranks #999999 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Geratherm Medical AG has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Geratherm Medical AG's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Geratherm Medical AG ranks #999999 out of 472 companies for EV-to-EBIT. This places Geratherm Medical AG in the lower half of its industry. The industry median EV-to-EBIT is 19.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.67, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Geratherm Medical AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geratherm Medical AG's current EV-to-EBIT is -8.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geratherm Medical AG stock overvalued right now?
Based on GuruFocus' analysis, Geratherm Medical AG (XTER:GME) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.13, compared to a current price of €2.53 — trading 19.2% below its estimated fair value. The current EV-to-EBIT is -8.19. Geratherm Medical AG's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Geratherm Medical AG (XTER:GME), the current EV-to-EBIT is -8.19 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geratherm Medical AG (XTER:GME) Overvalued in 2026?
Based on GuruFocus' analysis, Geratherm Medical AG stock appears to be undervalued.
The current stock price of €2.53 is trading 19.2% below its estimated GF Value™ of €3.13.
GuruFocus considers Geratherm Medical AG to be Modestly Undervalued.
Key valuation signals for XTER:GME:
EV-to-EBIT: -8.19
GF Value™: €3.13 vs. price of €2.53 (19.2% below fair value)
No single metric tells the full story. See the XTER:GME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics.
72GF Score
Get the complete analysis for XTER:GME
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:GME has been successfully added to your 
